MSD Partners L.P. Has $1.07 Million Stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT)

MSD Partners L.P. reduced its position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRTFree Report) by 33.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,151,516 shares of the company’s stock after selling 7,575,758 shares during the quarter. Alaunos Therapeutics accounts for approximately 0.1% of MSD Partners L.P.’s investment portfolio, making the stock its 13th biggest holding. MSD Partners L.P. owned approximately 94.40% of Alaunos Therapeutics worth $1,071,000 at the end of the most recent reporting period.

Alaunos Therapeutics Stock Performance

NASDAQ TCRT remained flat at $0.95 on Friday. 11,263 shares of the company’s stock traded hands, compared to its average volume of 140,959. The business has a 50 day simple moving average of $1.22 and a two-hundred day simple moving average of $1.52. Alaunos Therapeutics, Inc. has a 1 year low of $0.66 and a 1 year high of $7.96.

Alaunos Therapeutics (NASDAQ:TCRTGet Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Alaunos Therapeutics Profile

(Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.

Further Reading

Institutional Ownership by Quarter for Alaunos Therapeutics (NASDAQ:TCRT)

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with's FREE daily email newsletter.